These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

929 related items for PubMed ID: 25483647

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH, Thakur M, Boaz M, Johnson C.
    Vaccine; 2013 Oct 17; 31(44):5047-54. PubMed ID: 24021313
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL, Park J, López-Medina E, Capeding MR, Cadena Bonfanti AA, Montalbán MC, Ramírez I, Gonzales MLA, DiazGranados CA, Zambrano B, Dayan G, Savarino S, Chen Z, Wang H, Sun S, Bonaparte M, Rojas A, Ramírez JC, Verdan MA, Noriega F.
    Lancet Infect Dis; 2021 Apr 17; 21(4):517-528. PubMed ID: 33212067
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR, Morales JJR, De Los Santos AHM, Rivas E, Vigne C, Noriega F.
    Pediatr Infect Dis J; 2017 Jun 17; 36(6):602-608. PubMed ID: 28067718
    [Abstract] [Full Text] [Related]

  • 7. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G.
    Pediatr Infect Dis J; 2011 Jan 17; 30(1):e9-17. PubMed ID: 21042231
    [Abstract] [Full Text] [Related]

  • 8. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
    Torresi J, Richmond PC, Heron LG, Qiao M, Marjason J, Starr-Spires L, van der Vliet D, Jin J, Wartel TA, Bouckenooghe A.
    J Infect Dis; 2017 Oct 17; 216(7):834-841. PubMed ID: 28968794
    [Abstract] [Full Text] [Related]

  • 9. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
    Tran NH, Chansinghakul D, Chong CY, Low CY, Shek LP, Luong CQ, Fargo C, Wartel TA, Sun S, Skipetrova A, Bouckenooghe A.
    Hum Vaccin Immunother; 2019 Oct 17; 15(10):2315-2327. PubMed ID: 30724660
    [Abstract] [Full Text] [Related]

  • 10. The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.
    Glass A, Polhemus M, Wang D, Jarman RG, Thomas SJ, Friberg H, Currier JR, Bonaparte M, De La Barra R, Princiotta MF, Abbott M, Cuzzo B, Machabert T, Sridhar S, Endy TP.
    J Infect Dis; 2020 Mar 16; 221(7):1057-1069. PubMed ID: 31755526
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
    Henein S, Swanstrom J, Byers AM, Moser JM, Shaik SF, Bonaparte M, Jackson N, Guy B, Baric R, de Silva AM.
    J Infect Dis; 2017 Feb 01; 215(3):351-358. PubMed ID: 27932620
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V, Mantel N, De Montfort A, Pagnon A, Pradezynski F, Lang J, Boudet F.
    J Virol; 2018 Jun 15; 92(12):. PubMed ID: 29593041
    [Abstract] [Full Text] [Related]

  • 17. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
    Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, Hu B, Saville M, Chansinghakul D, Noriega F, Plennevaux E.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2004-2016. PubMed ID: 28598256
    [Abstract] [Full Text] [Related]

  • 18. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT.
    J Infect Dis; 2015 Oct 01; 212(7):1032-41. PubMed ID: 25791116
    [Abstract] [Full Text] [Related]

  • 19. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
    Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, Nissen MD, Richmond PC.
    Vaccine; 2015 Sep 22; 33(39):5127-34. PubMed ID: 26279339
    [Abstract] [Full Text] [Related]

  • 20. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.
    Ravel G, Mantel N, Silvano J, Rogue A, Guy B, Jackson N, Burdin N.
    Vaccine; 2017 Oct 13; 35(43):5918-5923. PubMed ID: 28882438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.